Experimental drug IC14 targets heart inflammation in rare disease
NCT ID NCT06275893
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 28 times
Summary
This early-phase trial tested a drug called IC14 in one person with arrhythmogenic cardiomyopathy, a rare heart condition that can cause dangerous heart rhythms. The goal was to see if the drug is safe and reduces inflammation, using blood tests and heart monitoring. The study did not include a placebo group and focused on measuring changes from the participant's own starting point.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.